Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Splicing modulator H3B-8800 in myeloid malignancies: phase 1 results

David Steensma • 8 Dec 2019
ASH 2019
Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Leukemia Myelodysplastic Syndromes Rare Diseases H3B-8800

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a clinical trial of H3B-8800, a splicing modulator, in myeloid cancers (NCT02841540). This phase I, open-label, first-in-human study explored the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of H3B-8800 in patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from David Steensma

2:51
MDS and Agent Orange
David Steensma • 5 Mar 2020
0:43
MDS novel agents & HMAs
David Steensma • 5 Mar 2020
0:52
Azacitidine in the treatment of MDS
David Steensma • 5 Mar 2020
1:16
State of the art: MDS
David Steensma • 5 Mar 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals